JP2018523484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523484A5 JP2018523484A5 JP2018509542A JP2018509542A JP2018523484A5 JP 2018523484 A5 JP2018523484 A5 JP 2018523484A5 JP 2018509542 A JP2018509542 A JP 2018509542A JP 2018509542 A JP2018509542 A JP 2018509542A JP 2018523484 A5 JP2018523484 A5 JP 2018523484A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cell
- nucleic acid
- acid sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 110
- 210000004027 cell Anatomy 0.000 claims description 62
- 150000007523 nucleic acids Chemical group 0.000 claims description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 125000006850 spacer group Chemical group 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 19
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 230000020411 cell activation Effects 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 230000005754 cellular signaling Effects 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000008045 co-localization Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000001960 triggered effect Effects 0.000 claims description 2
- 239000013638 trimer Substances 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514874.5 | 2015-08-20 | ||
| GBGB1514874.5A GB201514874D0 (en) | 2015-08-20 | 2015-08-20 | Cell |
| PCT/GB2016/052563 WO2017029511A1 (en) | 2015-08-20 | 2016-08-19 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020194900A Division JP2021027841A (ja) | 2015-08-20 | 2020-11-25 | 細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523484A JP2018523484A (ja) | 2018-08-23 |
| JP2018523484A5 true JP2018523484A5 (enExample) | 2019-07-25 |
| JP7395249B2 JP7395249B2 (ja) | 2023-12-11 |
Family
ID=54292002
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509542A Active JP7395249B2 (ja) | 2015-08-20 | 2016-08-19 | 細胞 |
| JP2020194900A Withdrawn JP2021027841A (ja) | 2015-08-20 | 2020-11-25 | 細胞 |
| JP2023180246A Pending JP2023178386A (ja) | 2015-08-20 | 2023-10-19 | 細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020194900A Withdrawn JP2021027841A (ja) | 2015-08-20 | 2020-11-25 | 細胞 |
| JP2023180246A Pending JP2023178386A (ja) | 2015-08-20 | 2023-10-19 | 細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11365262B2 (enExample) |
| EP (1) | EP3337501A1 (enExample) |
| JP (3) | JP7395249B2 (enExample) |
| CN (1) | CN108135984A (enExample) |
| AU (1) | AU2016308617A1 (enExample) |
| CA (1) | CA2995775A1 (enExample) |
| GB (1) | GB201514874D0 (enExample) |
| HK (1) | HK1250667A1 (enExample) |
| WO (1) | WO2017029511A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| GB201620070D0 (en) * | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| AU2018236450A1 (en) | 2017-03-16 | 2019-10-03 | The General Hospital Corporation | Chimeric antigen receptors targeting CD37 |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| CN110636851B (zh) | 2017-03-27 | 2023-11-03 | 新加坡国立大学 | 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| US11596655B2 (en) | 2017-04-27 | 2023-03-07 | Washington University | Activation of natural cytotoxicity receptor 2 (NCR2) |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| JP2021500930A (ja) * | 2017-11-01 | 2021-01-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｏｍｐボディ−多価標的結合物質 |
| US20190192678A1 (en) * | 2017-12-18 | 2019-06-27 | Novather, Inc. | System and method for the treatment of disease using a hyperspecific modified protein system |
| CA3089319A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| BR112020015884A2 (pt) | 2018-02-06 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple |
| CA3089170A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US12240870B2 (en) | 2018-02-23 | 2025-03-04 | Purdue Research Foundation | Sequencing method for CAR T cell therapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| KR20210066865A (ko) | 2018-09-27 | 2021-06-07 | 오토러스 리미티드 | 키메라 항원 수용체 |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20220259281A1 (en) * | 2019-06-21 | 2022-08-18 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| US12428476B2 (en) * | 2019-07-11 | 2025-09-30 | Valkyr, Inc. | System and methods relating to chimeric autoantibody receptors |
| CN112779223B (zh) * | 2019-11-08 | 2024-06-11 | 浙江煦顼技术有限公司 | 偶联嵌合抗原受体细胞及其用途 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| US9447194B2 (en) | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| RU2717984C2 (ru) * | 2013-11-21 | 2020-03-27 | ЮСиЭл БИЗНЕС ЛТД | Клетка |
| AU2014366047B2 (en) | 2013-12-19 | 2021-03-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
-
2015
- 2015-08-20 GB GBGB1514874.5A patent/GB201514874D0/en not_active Ceased
-
2016
- 2016-08-19 US US15/753,505 patent/US11365262B2/en active Active
- 2016-08-19 JP JP2018509542A patent/JP7395249B2/ja active Active
- 2016-08-19 EP EP16756757.7A patent/EP3337501A1/en active Pending
- 2016-08-19 HK HK18110271.9A patent/HK1250667A1/zh unknown
- 2016-08-19 CN CN201680046855.5A patent/CN108135984A/zh active Pending
- 2016-08-19 CA CA2995775A patent/CA2995775A1/en not_active Abandoned
- 2016-08-19 WO PCT/GB2016/052563 patent/WO2017029511A1/en not_active Ceased
- 2016-08-19 AU AU2016308617A patent/AU2016308617A1/en not_active Abandoned
-
2020
- 2020-11-25 JP JP2020194900A patent/JP2021027841A/ja not_active Withdrawn
-
2023
- 2023-10-19 JP JP2023180246A patent/JP2023178386A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523484A5 (enExample) | ||
| JP2016538855A5 (enExample) | ||
| RU2016124278A (ru) | Клетка | |
| JP2016538854A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| JP7253020B2 (ja) | キメラ抗原受容体およびその使用 | |
| JP2022109953A5 (enExample) | ||
| JP2019150066A5 (enExample) | ||
| JP2021035395A5 (enExample) | ||
| JP2018532407A5 (enExample) | ||
| CN112638947B (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| RU2017121892A (ru) | Клетка | |
| KR102588292B1 (ko) | 항-bcma 키메라 항원 수용체 | |
| US20200368268A1 (en) | Immune-enhancing rnas for combination with chimeric antigen receptor therapy | |
| JP2018523485A5 (enExample) | ||
| JP2018501794A5 (enExample) | ||
| JP2018517410A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| JP2018521663A (ja) | 治療薬 | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| JP2019514393A (ja) | 細胞に基づくネオ抗原ワクチンおよびその使用 | |
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| JP2018523484A (ja) | 細胞 | |
| JP2017537622A5 (enExample) | ||
| JP2017513478A5 (enExample) |